Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Receivables (2016 - 2025)

Historic Receivables for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $707.3 million.

  • Neurocrine Biosciences' Receivables rose 4332.32% to $707.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $707.3 million, marking a year-over-year increase of 4332.32%. This contributed to the annual value of $707.3 million for FY2025, which is 4332.32% up from last year.
  • Per Neurocrine Biosciences' latest filing, its Receivables stood at $707.3 million for Q4 2025, which was up 4332.32% from $728.0 million recorded in Q3 2025.
  • Neurocrine Biosciences' 5-year Receivables high stood at $728.0 million for Q3 2025, and its period low was $151.0 million during Q1 2021.
  • Moreover, its 4-year median value for Receivables was $463.3 million (2024), whereas its average is $439.8 million.
  • In the last 5 years, Neurocrine Biosciences' Receivables tumbled by 150.03% in 2021 and then skyrocketed by 5131.99% in 2025.
  • Over the past 4 years, Neurocrine Biosciences' Receivables (Quarter) stood at $166.6 million in 2021, then soared by 170.41% to $450.5 million in 2023, then increased by 9.54% to $493.5 million in 2024, then soared by 43.32% to $707.3 million in 2025.
  • Its Receivables stands at $707.3 million for Q4 2025, versus $728.0 million for Q3 2025 and $595.7 million for Q2 2025.